Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?

Spiliotis, John

doi:10.21037/atm-20-1486

Cited by 4 publications

(4 citation statements)

References 47 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin has been used more often and is recommended in the NCCN guidelines. Drugs used in our study included cisplatin, lobaplatin, and paclitaxel, either alone or in combination, which was not identical to previously reported usage ( 34 ). In fact, not only do the types of chemotherapy drugs used in HIPEC differ in reported articles but parameters including drug dosage, goal temperature, and duration of perfusion also vary widely ( 5 ).…”

Section: Discussionmentioning

confidence: 67%

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

et al. 2022

View full text Add to dashboard Cite

ObjectiveTo study the efficacy of interval debulking surgery (IDS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) compared to IDS alone for the treatment of ovarian cancer after neoadjuvant chemotherapy (NACT).MethodsWe conducted a retrospective study of patients with stage IIIC/IV high-grade serous ovarian carcinoma who underwent surgery at our center from January 2018 to December 2019. Patients who underwent IDS after NACT with (N = 20) or without (N = 42) HIPEC were included. HIPEC was administered after surgery and was combined with 1–2 courses of intraperitoneal hyperthermic perfusion with normal saline only. We analyzed clinical information and outcomes for the two groups.ResultsThe median progression-free survival (PFS) was 14.05 months in the IDS plus HIPEC group and 12.97 months in the IDS group (P = 0.597). The median overall survival (OS) was not reached. After adjustment for age between the two groups, the differences in PFS and OS remained nonsignificant. The change ratio of postoperative CA-125 to preoperative CA-125 was 0.66 in the IDS plus HIPEC group and 0.53 in the IDS group (P = 0.341). The difference in human epididymis protein 4 (HE-4) change ratio between the two groups was nonsignificant (P = 0.225). No significant difference was observed in the occurrence of grade 3 and 4 adverse events between the two groups (P = 0.201).ConclusionAfter NACT, IDS plus HIPEC did not show significant PFS and tumor index change ratio benefits over IDS alone in patients with primary ovarian cancer. Further investigations are needed to assess the role of HIPEC in the treatment of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 67%

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It was affirmed by another crucial observation that the result of HIPEC is related to PCI; thus, the chance to reach optimal cytoreduction significantly increased. This treatment should be emphasized at experienced centers and used by well-trained multidisciplinary groups following a targeted and precise selection of patients [ 61 ].…”

Section: Ovarian Cancermentioning

confidence: 99%

Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Acs,

Babucke,

Jusufi

et al. 2024

Innovative Surgical Sciences

View full text Add to dashboard Cite

Treatment of peritoneal surface malignancies makes physicians face demanding and new-fangled problems, as there are many uncertain aspects considering the outcomes of affected patients’ prognoses. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are associated with favorable long-term outcomes in carefully selected patients with peritoneal metastases (PM). We aim to summarize the current results about the initial malignancies and their peritoneal spreads. The current literature has been scrutinized, and studies between 2016 and 2022 were included wherein long-term, progression-free (PFS), and overall survival (OS) data were considered relevant information. Medline, Embase, and Google Scholar have been the main sources. Hereby, we cover all the primer malignancies: gastric, ovarian, and colorectal cancers with peritoneal metastases (PM), malignant peritoneal mesothelioma, and pseudomyxoma peritonei. Examining the advances in the current peer-reviewed literature about the indications of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), target groups, risk factors, and other influencing elements, we intend to provide a complex state-of-the-art report, establishing the relevant aspects of that emerging treatment method.

show abstract

“…However, 80% of women with advanced disease EOC will recur despite the appropriate treatment approach mentioned above 3,4 .…”

Section: Managementmentioning

confidence: 99%

A review analysis of cytoreductive surgery and HIPEC in gynecological cancers

Spiliotis¹,

Noskova²,

Spiliotis³

2022

Int. J. Front. Med. Surg. Res.

View full text Add to dashboard Cite

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure to delivered chemotherapy directly while heating in the peritoneal cavity after a special surgical effort which described as cytoreductive surgery (CRS). The aim of this method is to eliminate surgically and medically all the visible tumor deposits from different tumors. The last decade the interest of this treatment in peritoneal metastasis of different gynecological tumors as ovarian, endometrial or cervical are reported with different trials. This article reviews the current literature and evidence of this procedure.

show abstract

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?

Cited by 4 publications

References 47 publications

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

A review analysis of cytoreductive surgery and HIPEC in gynecological cancers

Contact Info

Product

Resources

About